2+ can alter systemic and renal vascular tone. However, the mechanism of these effects is not known. The role of vasodilator prostaglandin release and Ca 2+ flux in Mg 2+ -induced changes in blood pressure and renal blood flow was studied in 10 normal subjects maintained on a fixed 80-mEq Na + and K + diet. Magnesium sulfate infused at 200 mg/hr for 3 hours reduced systolic and diastolic blood pressure within 1 hour (from 119 ± 2 [SEM] to 109 ± 4 mm Hg systolic; from 74 ± 3 to 64 ± 4 mm Hg diastolic; p<0.02). This hypotensive response was seen in all subjects and persisted for 3 hours. The pulse rate did not change, but renal blood flow (p-aminohippurate clearance) increased (from 902 ± 78 to 1108 ± 130 ml/min/1.73 m 2 ; p<0.05). The Mg 2+ infusion produced a significant increase in the excretion of the stable prostaglandin I 2 (PGIj) metabolite 6-keto-PGF la (from 96 ± 12 to 154 ± 16 ng/g creatinine; p<0.01). In contrast, urinary PGEj was not altered (328 ± 75 vs 399 ± 145 ng/g creatinine; p>0.6).
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SUMMARY Evidence in vitro and in humans suggests that Mg 2+ can alter systemic and renal vascular tone. However, the mechanism of these effects is not known. The role of vasodilator prostaglandin release and Ca 2+ flux in Mg 2+ -induced changes in blood pressure and renal blood flow was studied in 10 normal subjects maintained on a fixed 80-mEq Na + and K + diet. Magnesium sulfate infused at 200 mg/hr for 3 hours reduced systolic and diastolic blood pressure within 1 hour (from 119 ± 2 [SEM] to 109 ± 4 mm Hg systolic; from 74 ± 3 to 64 ± 4 mm Hg diastolic; p<0.02). This hypotensive response was seen in all subjects and persisted for 3 hours. The pulse rate did not change, but renal blood flow (p-aminohippurate clearance) increased (from 902 ± 78 to 1108 ± 130 ml/min/1.73 m 2 ; p<0.05). The Mg 2+ infusion produced a significant increase in the excretion of the stable prostaglandin I 2 (PGIj) metabolite 6-keto-PGF la (from 96 ± 12 to 154 ± 16 ng/g creatinine; p<0.01). In contrast, urinary PGEj was not altered (328 ± 75 vs 399 ± 145 ng/g creatinine; p>0.6).
To evaluate the functional role of PGIj release, the cyclooxygenase inhibitors indomethacin (75 mg) or ibuprofen (600 mg) were given before the Mg* + infusion. Both cyclooxygenase blockers, given in doses that inhibited immunoreactive 6-keto-PGF, a release, completely prevented the Mg 2+ -induced decline in blood pressure and increased renal blood flow. In addition, pretreatment with the Ca 2+ channel antagonist nifedipine (20 PGI 2 production was estimated by radioimmunoassay of the stable PGI 2 metabolite 6-keto-PGF la in urine, as previously described. 12 In brief, an acidified urine sample with authentic [ 3 H]6-keto-PGF la (New England Nuclear, Boston, MA, USA) added for recovery is extracted with ethyl acetate and then purified on high resolution Sephadex LH-20 columns (80 x 1 cm), which separates the major prostaglandin metabolites, including 2,3-dinor-6-keto-PGF la . The peak fraction, as determined by [ 3 H]6-keto-PGF la , is then assayed using a sensitive and specific 6-keto-PGF la antisera, 13 and a second antibody method is used to separate bound from free ligand.
14 Recovery of added tracer averages 60 ± 6%. Interassay variation is 12%, and intraassay variation is 6%. Sensitivity is 10 pg/ml, and the assay blank averages 2 pg/ml. This assay has been validated with several techniques including negative-ion gas chromatography-mass spectrometry. 10 In addition, urinary PGEj excretion was determined by a published radioimmunoassay method after several purification steps.
14 Infusions were performed during the same time of day (1300-1600) and in nonsmoking subjects, since both time of day and smoke inhalation can alter 6-keto-PGF ln excretion in hulnans. 15 ' " Values are reported as the mean ± SEM. Prostaglandin values are expressed in units of nanograms per gram of creatinine. Each subject was used as his or her own control and prostaglandin samples were run in the same assay. For statistical analysis the paired t test was used to compare control and experimental values using a CLINFO computer system.
Results

Infusion Alone
The infusion produced a significant rise in serum Mg 2+ concentration (Table 1) . Systolic and diastolic blood pressure was reduced within 1 hour of Mg 2+ administration (from 119 ± 2 to 109 ± 4 mm Hg systolic; from 74 ± 3 to 64 ± 4 mm Hg diastolic; p<0.02). This hypotensive response persisted for 3 hours (Figures 1 and 2) . The pulse rate did not change (68 ± 4 vs 72 ± 2 beats/min; /?>0.5), while renal blood flow was significantly increased (from 902 ± 78 to 1108 ± 130 ml/min/1.73 m 2 ; p < 0 . 0 5 ; Figure 3 ). The Mg 2+ infusion produced a marked increase in the excretion of immunoreactive 6-keto-PGF la (from 96 ± 12 to 154 ± 16 ng/g creatinine;p<0.01; Figure  4 ). However, urinary PGEj levels were not altered (328 ± 75 vs 399 ± 145 ng/g creatinine; p > 0 . 6 ) .
Effect of Cyclooxygenase Inhibition
The Mg 2+ infusion in subjects who were pretreated with indomethacin or ibuprofen produced changes in serum and urinary Mg 2+ similar to those seen with the Mg 2 * infusion alone (see Table 1 ). However, the use of cyclooxygenase blockers totally prevented the Mg 2+ -induced decrease in systolic and diastolic blood pressure (see Figures 1 and 2) . Several subjects showed increases in blood pressure. The pulse rate did not change (71 ± 2 vs 68 ± 2; p>0A). Similarly renal blood flow did not increase, and values were similar to baseline (850 ± 125 vs 902 ± 78; p>0A; see Figure 3 ).
The cyclooxygenase blockers given alone did not alter basal blood pressure (114 ± 3 mm Hg systolic; 
FIGURE 2. Effect of MgSO 4 infusion alone C) or with cyclooxygenase inhibition (o) on diastolic blood pressure (BP). Asterisk indicates significant difference (p<0.01, paired Student's t test).
FIGURE 4. Effect of MgSO 4 infusion alone or with nifedipine (N) on immunoreactive 6-keto-prostaglandin F, a (PGF,J excretion. Values are means ± SEM. Asterisk indicates significant difference (p<0.01, paired Student's t test).
74 ± 6 mm Hg diastolic) or renal blood flow (896 ± 80 ml/min/1.73 m 2 ). Both indomethacin and ibuprofen completely prevented the Mg 2+ -induced rise of 6-keto-PGF la and produced levels similar to control (82 ± 22 vs 95 ± 12 ng/g creatinine; p>0.4).
Effect of Ca 2+ Channel Blockade
Pretreatment with nifedipine did not alter the increase in serum or urinary Mg 2+ levels after Mg 2+ administration (see Table 1 ). However, urinary Mg 2+ excretion was slightly higher when compared with the Mg 2+ infusion during cyclooxygenase inhibition (see Table 1 ).
Systolic and diastolic blood pressure remained unchanged during the Mg 2+ infusion with nifedipine (116 ± 4 vs 114 ± 2 mm Hg systolic; 76 ± 4 vs 72 ± 3 mm Hg diastolic; p>0.5). In addition, nifedipine completely blocked the Mg 2+ -stimulated rise of 6-keto-PGF la excretion (see Figure 4 ) and produced levels similar to control levels.
Discussion
The vasodilator effects of Mg
2+ have been known for many years. In 1942, administration of Mg 2+ to subjects with hypertension was shown to reduce blood pressure. 17 More recent evidence indicates that Mg 2+ supplementation can enhance the hypotensive effect of diuretic therapy. 18 A deficiency of cellular Mg 2+ content can markedly potentiate the sensitivity of blood vessels to pressor agents, 12 and intracellular Mg 2+ levels are reduced in untreated essential hypertensive subjects. 19 Therefore, Mg 2+ deficiency may play a role in the development and maintenance of essential hypertension.
The current study in normal subjects reveals that MgSO 4 infusion significantly reduces systolic and dia-382 HYPERTENSION VOL 9, No 4, APRIL 1987 stolic blood pressure and increases renal blood flow. These results are similar to those in a previous study 20 and indicate that Mg 2+ can alter systemic and renal vascular tone. 25 Considerable evidence suggests that the vasodilator prostaglandins PGI 2 and PGF^ participate as protective modulators of systemic and renal blood flow during states of increased pressor activity or ischemia. 26 " 28 In addition, PGI 2 has been shown to be a key mediator of the vasodilator actions of bradykinin. 29 In the present study, the Mg 2+ -induced decrease in blood pressure and increase in renal blood flow were completely blocked by pretreatment with two structurally distinct cyclooxygenase inhibitors, suggesting that vasodilator prostaglandin release mediates the vascular action of Mg 2+ . The MgSO 4 infusion selectively increased PGI 2 formation, as reflected by immunoreactive 6-keto-PGF la in urine, indicating that PGI 2 is the major vascular prostaglandin mediating these effects. Under basal conditions urinary 6-keto-PGF ]a primarily reflects renal vascular PGT 2 production, 30 while another PGI 2 metabolite, 2,3-dinor-6-keto-PGF la , generally reflects extrarenal PGI 2 production. However, systemic PGI 2 formation can produce a rise in urinary 6-keto-PGF la under stimulated conditions. 31 Therefore, the increase in immunoreactive 6- since other studies show that bradykinin-stimulated release of PGI 2 is also calcium-dependent. 33 -
M
The increased excretion of immunoreactive 6-keto-PGF la does not appear to be secondary to changes in renal blood flow. Previous studies in humans indicate that vasodilators that can increase renal blood flow, such as isoproterenol, nifedipine, and prazosin, do not increase immunoreactive 6-keto-PGF, a levels. 1012 In addition, vasopressor agonists, such as angiotensin II and norepinephrine, either do not change or increase 6-keto-PGF la levels. 13 The precise reason for the selective increase in PGI 2 without changes in PGE, is not totally clear from this study. One possible explanation is that PGF^ is less sensitive in vitro and in humans to changes in Ca 2+ flux. 10 -35 In addition, studies in renal medullary tissue indicate that increases in Mg 2+ do not stimulate PGE; synthesis. 36 Therefore, arachidonic acid released in response to changes in extracellular Mg 2+ in humans is converted primarily into PGI 2 , resulting in unaltered levels of PGEj.
In summary, these results suggest that PGI 2 release plays a key role in the systemic and renal vasodilator effects of Mg 2+ . These findings may provide a physiological basis for the use of Mg 2+ in disorders of altered vascular tone such as essential hypertension and preeclampsia.
